Does Testosterone Replacement Increase Gastric Acid Production?
No, testosterone replacement therapy does not increase stomach acid production in humans, and the available evidence from FDA labeling, clinical guidelines, and human studies does not identify gastric acid hypersecretion as a recognized adverse effect of testosterone therapy.
Evidence from FDA Drug Labeling
The FDA-approved prescribing information for testosterone cypionate injection lists multiple adverse effects and precautions but does not mention increased gastric acid production, gastroesophageal reflux, peptic ulcer disease, or any gastrointestinal effects related to acid hypersecretion 1. The documented gastrointestinal side effects are limited to nausea and vomiting, which are nonspecific symptoms unrelated to acid production 1.
Evidence from Clinical Guidelines
Major clinical practice guidelines from the American College of Physicians, Endocrine Society, American Urological Association, and European Association of Urology do not list gastric acid-related complications among the recognized risks of testosterone therapy 2, 3, 4, 5. These comprehensive guidelines detail cardiovascular risks, erythrocytosis, prostate effects, sleep apnea, fluid retention, and fertility suppression, but gastric acid hypersecretion is conspicuously absent from all monitoring recommendations and adverse-effect profiles 2, 3, 4, 5.
Animal Research vs. Human Clinical Reality
Rodent Studies Show Conflicting Results
- In a 1979 rat study, testosterone propionate injections increased gastric acid output while decreasing mucus secretion, with effects opposite to those of estrogen 6.
- A 1970 study in castrated male rats found that testosterone had inconsistent effects on acid secretion, with statistically significant reduction only when gastrin was used as the secretagogue (p < 0.05), but not with histamine 7.
- A 2008 study demonstrated that testosterone (0.01–10 mg/kg/day) dose-dependently delayed gastric ulcer healing in rats, attributed to increased gastric acid secretion, reduced blood flow at ulcer margins, and elevated proinflammatory cytokines (IL-1β and TNF-α) 8.
Why Animal Data Do Not Apply to Humans
These rodent studies used supraphysiologic testosterone doses, employed different hormonal milieux than human hypogonadism, and measured acute pharmacologic effects rather than chronic replacement therapy 8, 6, 7. The doses used in these experiments (up to 10 mg/kg/day in rats) far exceed the physiologic replacement doses used in human testosterone therapy (typically 100–200 mg every 2 weeks intramuscularly, targeting mid-normal serum levels of 500–600 ng/dL) 3.
Critically, if testosterone meaningfully increased gastric acid production in humans, this would have emerged as a recognized adverse effect in the extensive clinical trial literature and post-marketing surveillance data spanning decades of testosterone use 2, 3, 4, 5. The absence of any such signal in human data strongly argues against clinical relevance.
Monitoring Recommendations Do Not Include Gastric Symptoms
Standard monitoring protocols for testosterone therapy focus on hematocrit (withhold if >54%), PSA levels (refer to urology if rise >1.0 ng/mL in first 6 months or >0.4 ng/mL/year thereafter), cardiovascular symptoms, and prostate examination 2, 3. No guideline recommends screening for or monitoring gastric acid-related symptoms such as heartburn, dyspepsia, or peptic ulcer disease 2, 3, 4, 5.
Clinical Bottom Line
For adult males receiving testosterone replacement therapy for confirmed hypogonadism, gastric acid production is not a clinical concern, does not require monitoring, and should not influence treatment decisions 2, 3, 4, 5, 1. The documented risks of testosterone therapy—erythrocytosis (15–44% depending on formulation), cardiovascular events in high-risk populations, prostate effects, and fertility suppression—warrant attention, but gastric acid hypersecretion does not 2, 3, 4, 5.
Common Pitfall to Avoid
Do not extrapolate findings from animal studies using supraphysiologic testosterone doses to human replacement therapy, as the hormonal context, dosing, and physiologic responses differ fundamentally 8, 6, 7. The absence of gastric acid effects in all human clinical guidelines and FDA labeling confirms that this is not a clinically relevant concern 2, 3, 4, 5, 1.